Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT02989714
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2024-11-22
- Target Recruit Count
- 27
- Registration Number
- NCT02964078
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Anti-infection of Low-does IL-2 in SLE
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT02932137
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing, China
TIL Therapy for Metastatic Renal Cell Carcinoma
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 5
- Registration Number
- NCT02926053
- Locations
- 🇩🇰
Center for Cancer Immune Therapy Dept. of Hematology/oncology, Herlev, Denmark
PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Peking University
- Registration Number
- NCT02867345
- Locations
- 🇨🇳
Department of Urology Peking University First Hospital, Beijing, Beijing, China
PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
- Conditions
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Peking University
- Registration Number
- NCT02867332
PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Peking University
- Registration Number
- NCT02863913
- Locations
- 🇨🇳
Department of Urology Peking University First Hospital, Beijing, Beijing, China
Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 9
- Registration Number
- NCT02845999
- Locations
- 🇫🇷
University hospital of Besançon, Besançon, France
Response-based Treatment of High-risk Neuroblastoma
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 54
- Registration Number
- NCT02771743
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
- Conditions
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2020-10-05
- Target Recruit Count
- 7
- Registration Number
- NCT02763475
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
🇪🇸Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain
🇪🇸Hospital Materno Infantil de Badajoz, Badajoz, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.